EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 25 April 2016 00:00
- Written by Liz Highleyman
Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history of HCC, according to research presented at the recent European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona. These findings underline the importance of ongoing liver cancer monitoring even after successful hepatitis C treatment.
More Articles...
- EASL 2016: Sofosbuvir/ Ledipasvir for 6 Weeks Cures Acute Hepatitis C in HIV-Negative People
- EASL 2016: Hepatitis C Treatment May Not Stop Progression to Advanced Liver Disease
- CROI 2016: Harvoni for 6 Weeks Cures HIV+ People with Acute HCV if Viral Load is Low
- AASLD 2015: Sofosbuvir Plus Ribavirin Shows Suboptimal Efficacy for Acute Hepatitis C
- AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
Web Design and Development by